Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Acuitas Therapeutics Inc. currently manages 8 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 8 distinct examiners and 8 distinct art units. The presence of these 8 pending office actions shows the current volume of activity for this entity. Practitioners should note the distribution across the 8 distinct art units, which involves different examination environments. The coordination of responses across different technical centers is a key consideration for the legal team.
CHEN, PO-CHIH is the busiest examiner for this portfolio, currently overseeing 1 pending office action. While the company workload involves 8 distinct examiners, this specific official is responsible for 1 matter. This distribution suggests that the innovations are being evaluated by different groups within the Biotechnology & Pharmaceuticals field. Having 8 distinct examiners involved means that the prosecution strategy must account for the individual tendencies of various officials. Each examiner may bring a different perspective to the claims, requiring a specific approach for every individual case file.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| Double-patenting only | 1 (17%) |
| Multi-statute (no §101) | 4 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, PO-CHIH | 1 | 74.3% | +14.7% |
| HIRT, ERIN E | 1 | 40.6% | +22.9% |
| KETCHAM, KAREN A | 1 | 19.6% | +37.2% |
| ROSENTHAL, ANDREW S | 1 | 51.9% | +39.0% |
| ALSOMAIRY, SARAH ABDOALATIF | 1 | 57.4% | +30.7% |
| POPA, ILEANA | 1 | 21.7% | +15.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18744241 | AMIDE CONTAINING LIPIDS | ROSENTHAL, ANDREW S | 18d overdue |
| 18902591 | LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF ACTIVE AGENTS | CHEN, PO-CHIH | — |
| 18767373 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | HIRT, ERIN E | — |
| 18744246 | LIPIDS FOR USE IN LIPID NANOPARTICLES | KETCHAM, KAREN A | — |
| 18421751 | mRNA THERAPY WITH REDUCED IMMUNE REACTOGENICITY | ALSOMAIRY, SARAH ABDOALATIF | — |
| 17496530 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | POPA, ILEANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18744241 | AMIDE CONTAINING LIPIDS | ROSENTHAL, ANDREW S | 18d overdue |
| 18902591 | LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF ACTIVE AGENTS | CHEN, PO-CHIH | — |
| 18767373 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | HIRT, ERIN E | — |
| 18744246 | LIPIDS FOR USE IN LIPID NANOPARTICLES | KETCHAM, KAREN A | — |
| 18421751 | mRNA THERAPY WITH REDUCED IMMUNE REACTOGENICITY | ALSOMAIRY, SARAH ABDOALATIF | — |
| 17496530 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | POPA, ILEANA | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1616 | 1 |
| 1614 | 1 |
| 1613 | 1 |
| 1646 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18902591 | LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF ACTIVE AGENTS | CHEN, PO-CHIH | 1621 | §103§112Other | Non-Final OA | — | Pending | Sep 30, 2024 |
| 18767373 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | HIRT, ERIN E | 1616 | §102§103§112Other | Non-Final OA | — | Pending | Jul 09, 2024 |
| 18744246 | LIPIDS FOR USE IN LIPID NANOPARTICLES | KETCHAM, KAREN A | 1614 | §103 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18744241 | AMIDE CONTAINING LIPIDS | ROSENTHAL, ANDREW S | 1613 | §103§112 | Final Rejection | 18d overdue | Pending | Jun 14, 2024 |
| 18421751 | mRNA THERAPY WITH REDUCED IMMUNE REACTOGENICITY | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §102§103§112 | Non-Final OA | — | Pending | Jan 24, 2024 |
| 17496530 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | POPA, ILEANA | 1633 | DP | Final Rejection | — | Pending | Oct 07, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAcuitas Therapeutics Inc. has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
Po-Chih Chen has the most, with 1 of Acuitas Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
